Perry Dean Lewis, ARNP Hospitalist Medicare: Medicare Enrolled Practice Location: 401 Palmetto St, New Smyrna, FL 32168 Phone: 386-562-8718 |
News Archive
Intarcia Therapeutics, Inc. presented today the results of a phase 2 clinical study of ITCA 650 (DUROSĀ® continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes as a late-breaker at the Annual Conference of the American Diabetes Association in Orlando, FL (June 25-29, 2010). Results of the phase 2 study demonstrated substantial reductions in HbA1c and body weight during the 12 weeks of treatment with ITCA 650 at both the 20 mcg/day and 40 mcg/day doses.
Patients seen at the Cleveland Clinic Sleep Disorders Center who used positive airway pressure (PAP) to treat their obstructive sleep apnea (OSA) had improvements in their depressive symptoms, even if they followed the prescribed PAP regimen only partly, a new study reports.
H3 Biomedicine today announced that it has launched research and development operations in Cambridge, Massachusetts. H3 Biomedicine will undertake a comprehensive approach to breakthrough oncology treatments based on two primary principles: 1) the genetics of patients' cancers can reveal drug targets tailored to their cancers and 2) the advances in modern chemistry enable the discovery of new classes of safe and effective drugs against these targets.
Michel Kazatchkine - France's global ambassador for HIV/AIDS and communicable diseases who on Thursday was selected to be the new executive director of the Global Fund To Fight AIDS, Tuberculosis and Malaria - has announced that he will aim to improve the organization's partnerships with United Nations organizations and donors, the Boston Globe reports.
Expression of the microtubule-binding protein Tau is not a reliable means of selecting breast cancer patients for adjuvant paclitaxel chemotherapy, according to research led by The University of Texas M. D. Anderson Cancer Center.
› Verified 7 days ago